BioLineRx and Hemispherian report GLIX1 and olaparib synergy in ovarian cancer

July 8, 2026 7:00 AM

BioLineRx Ltd. (NASDAQ: BLRX, TASE: BLRX) and Hemispherian AS announced preclinical data showing a synergistic effect between GLIX1 and the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found